Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Condition(s):Non-small Cell Lung CancerLast Updated:April 25, 2023Suspended
Hide Studies Not Open or Pending
Condition(s):Non-small Cell Lung CancerLast Updated:April 25, 2023Suspended
Condition(s):GlioblastomaLast Updated:October 4, 2021Completed
Condition(s):Non-small Cell Lung Cancer; Adenocarcinoma; Stage IVLast Updated:May 11, 2023Recruiting
Condition(s):Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic; Multiple MyelomaLast Updated:September 20, 2017Withdrawn
Condition(s):Gastroesophageal AdenocarcinomaLast Updated:January 17, 2024Active, not recruiting
Condition(s):Lung Cancer, Nonsmall Cell, Stage ILast Updated:February 13, 2017Withdrawn
Condition(s):Resectable Biliary Tract CancerLast Updated:April 13, 2020Withdrawn
Condition(s):Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma; Extra Renal Origin; Clear Cell AdenocarcinomaLast Updated:July 27, 2023Active, not recruiting
Condition(s):Hepatocellular CarcinomaLast Updated:January 9, 2020Withdrawn
Condition(s):Liver CancerLast Updated:September 29, 2023Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.